These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 24343782)

  • 1. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection.
    Deeks ED
    Drugs; 2014 Feb; 74(2):195-206. PubMed ID: 24343782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
    Le Tiec C; Barrail A; Goujard C; Taburet AM
    Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Darunavir: a review of its use in the management of HIV infection in adults.
    McKeage K; Perry CM; Keam SJ
    Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection.
    Sherman EM; Worley MV; Unger NR; Gauthier TP; Schafer JJ
    Clin Ther; 2015 Sep; 37(9):1876-93. PubMed ID: 26319088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.
    Marzolini C; Gibbons S; Khoo S; Back D
    J Antimicrob Chemother; 2016 Jul; 71(7):1755-8. PubMed ID: 26945713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat.
    Renjifo B; van Wyk J; Salem AH; Bow D; Ng J; Norton M
    AIDS Rev; 2015; 17(1):37-46. PubMed ID: 25586481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Darunavir/cobicistat once daily for the treatment of HIV.
    Kakuda TN; Crauwels H; Opsomer M; Tomaka F; van de Casteele T; Vanveggel S; Iterbeke K; de Smedt G
    Expert Rev Anti Infect Ther; 2015 Jun; 13(6):691-704. PubMed ID: 25962100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
    Lennox JL; Landovitz RJ; Ribaudo HJ; Ofotokun I; Na LH; Godfrey C; Kuritzkes DR; Sagar M; Brown TT; Cohn SE; McComsey GA; Aweeka F; Fichtenbaum CJ; Presti RM; Koletar SL; Haas DW; Patterson KB; Benson CA; Baugh BP; Leavitt RY; Rooney JF; Seekins D; Currier JS;
    Ann Intern Med; 2014 Oct; 161(7):461-71. PubMed ID: 25285539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers.
    Kakuda TN; Opsomer M; Timmers M; Iterbeke K; Van De Casteele T; Hillewaert V; Petrovic R; Hoetelmans RM
    J Clin Pharmacol; 2014 Aug; 54(8):949-57. PubMed ID: 24644095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS.
    Putcharoen O; Do T; Avihingsanon A; Ruxrungtham K
    Drug Des Devel Ther; 2015; 9():5763-9. PubMed ID: 26566368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic enhancers in HIV therapeutics.
    Larson KB; Wang K; Delille C; Otofokun I; Acosta EP
    Clin Pharmacokinet; 2014 Oct; 53(10):865-72. PubMed ID: 25164142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
    Feng HP; Caro L; Fandozzi C; Chu X; Guo Z; Talaty J; Panebianco D; Dunnington K; Du L; Hanley WD; Fraser IP; Mitselos A; Denef JF; De Lepeleire I; de Hoon JN; Vandermeulen C; Marshall WL; Jumes P; Huang X; Martinho M; Valesky R; Butterton JR; Iwamoto M; Yeh WW
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boosting HIV treatment options: good news, new challenges.
    Cahn P; Sued O
    J Infect Dis; 2013 Jul; 208(1):4-6. PubMed ID: 23532095
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
    Khatri A; Dutta S; Wang H; Podsadecki T; Trinh R; Awni W; Menon R
    Clin Infect Dis; 2016 Apr; 62(8):972-9. PubMed ID: 26740513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
    Gallant JE; Koenig E; Andrade-Villanueva J; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Moyle G; Rizzardini G; Fehr J; Liu Y; Zhong L; Callebaut C; Szwarcberg J; Rhee MS; Cheng AK
    J Infect Dis; 2013 Jul; 208(1):32-9. PubMed ID: 23532097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atazanavir/ritonavir: a review of its use in HIV therapy.
    von Hentig N
    Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cobicistat: a new boost for the treatment of human immunodeficiency virus infection.
    Shah BM; Schafer JJ; Priano J; Squires KE
    Pharmacotherapy; 2013 Oct; 33(10):1107-16. PubMed ID: 23471741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rezolsta® (Darunavir/Cobicistat): First Boosted Protease Inhibitor Co-formulated with Cobicistat.
    Curran A; Pérez-Valero I; Moltó J
    AIDS Rev; 2015; 17(2):114-20. PubMed ID: 26035169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic Enhancement of HIV Antiretroviral Therapy During Pregnancy.
    Salama E; Eke AC; Best BM; Mirochnick M; Momper JD
    J Clin Pharmacol; 2020 Dec; 60(12):1537-1550. PubMed ID: 32798276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.
    Tomaka F; Lefebvre E; Sekar V; Van Baelen B; Vangeneugden T; Vandevoorde A; Diego Miralles G
    HIV Med; 2009 May; 10(5):318-27. PubMed ID: 19210693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.